OncoMatch/Clinical Trials/NCT04195347
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
Is NCT04195347 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CM4620 for acute pancreatitis.
Treatment: CM4620 — This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemotherapy will be determined. The effectiveness in reducing the severity of pancreatitis will be estimated. Primary Objectives To assess the safety of CM4620 administration in children and young adults with asparaginase associated pancreatitis (AAP). To profile dose-limiting toxicities and responses of the patients treated in the dose-finding phase. To estimate the efficacy of CM4620 to prevent pseudocyst or necrotizing pancreatitis in children with AAP. Secondary Objectives To determine the effect of CM4620 on the incidence of severe pancreatitis To determine the effect of CM4620 on the incidence of Systemic Inflammatory Response Syndrome (SIRS).
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: asparaginase
Cannot have received: investigational agent
Lab requirements
Cardiac function
QTc at baseline > 450 msec [excluded]
QTc at baseline > 450 msec. Creatinine > 3x the upper limit of normal for age or total bilirubin >3x the upper limit for normal for age without evidence of leukemic infiltrate or hemolysis.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Novant Health Presbyterian Hemby Children's Hospital · Charlotte, North Carolina
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify